Study of E7389 for Advanced or Metastatic Breast Cancer
NCT00965523
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
81
Enrollment
INDUSTRY
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
Eribulin Mesylate
Sponsor
Eisai Co., Ltd.